SCHEMBL80529

SCHEMBL80529

[CH2]C(=O)c1ccc(O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
HTT P42858 2/20 0.60
LMNA P02545 2/20 0.60
HPGD P15428 2/20 0.60
ESR1 P03372 1/20 0.60
ESR2 Q92731 1/20 0.60
PKM P14618 1/20 0.60
CA1 P00915 4/20 0.57
CA2 P00918 4/20 0.57
CA12 O43570 3/20 0.57
CA9 Q16790 3/20 0.57
CA14 Q9ULX7 3/20 0.57
CA7 P43166 2/20 0.57
CA3 P07451 2/20 0.57
TYR P14679 2/20 0.57
CA4 P22748 2/20 0.57
CA5A P35218 2/20 0.57
CA5B Q9Y2D0 2/20 0.57
DRD1 P21728 1/20 0.57
CA6 P23280 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenol SCHEMBL28080984 0.81 CES2 (0.56) MAPTLMNAHPGDPKMCA1
SCHEMBL1442016 0.79 MAPT (0.44) MAPTLMNACA1CA2CA12
SCHEMBL5842596 0.77 TSHR (0.71) CA1CA2CA12CA9CA14
SCHEMBL162830 0.77 PARP10 (0.74) MAPTHTTLMNAHPGDESR1
SCHEMBL28823636 0.77 PARP10 (0.74) MAPTHTTLMNAHPGDESR1
Hydroquinone SCHEMBL8674228 0.77 PARP10 (0.74) MAPTHTTLMNAHPGDESR1
SCHEMBL699850 0.75 LMNA (1.00) MAPTHTTLMNAHPGDESR1
SCHEMBL18423 0.75 LMNA (1.00) MAPTHTTLMNAHPGDESR1
SCHEMBL181662 0.75 CES2 (0.79) MAPTHTTLMNAHPGDESR1
Paraben SCHEMBL8968826 0.74 CA2 (0.89) MAPTHTTLMNAHPGDESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 592 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180932-A1 SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS NESTLE SA (CH) 2024-06-06 US claimed
US-11993801-B2 Base-modified nucleotides as substrates for TdT-based enzymatic nucleic acid synthesis ILLUMINA SINGAPORE PTE. LTD. (SG) 2024-05-28 US claimed
US-11897977-B2 Photolabile barbiturate compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-02-13 US claimed
EP-4313017-A1 SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS Société des Produits Nestlé S.A. (CH) 2024-02-07 EP claimed
US-20230414638-A1 SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF NESTLE SA (CH) 2023-12-28 US claimed
US-20230346942-A1 MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-11-02 US claimed
CN-116981452-A Substituted resorcinol compounds for the management of aging and related disorders 雀巢产品有限公司 2023-10-31 CN claimed
CN-116761791-A Substituted resorcinol compounds as AMPK activators and uses thereof 雀巢产品有限公司 2023-09-15 CN claimed
EP-4185707-A1 BASE-MODIFIED NUCLEOTIDES AS SUBSTRATES FOR TDT-BASED ENZYMATIC NUCLEIC ACID Illumina Singapore Pte Ltd (SG) 2023-05-31 EP claimed
CN-115867670-A Base-modified nucleotides as substrates for TDT-based enzyme nucleic acids 伊鲁米纳新加坡有限公司 2023-03-28 CN claimed
US-20060008907-A1 Control of gene expression via light activated RNA interference THE CURATORS OF THE UNIVERSITY OF MISSOURI 2006-01-12 US claimed
EP-1383748-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-01-28 EP claimed
WO-2002051983-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
EP-1073764-A4 MEMBRANE-PERMEANT PHOSPHOINOSITIDES UNIV CALIFORNIA (US) 2001-11-14 EP claimed
EP-1073764-A1 MEMBRANE-PERMEANT PHOSPHOINOSITIDES The Regents of the University of California (US) 2001-02-07 EP claimed
WO-1999055903-A1 MEMBRANE-PERMEANT PHOSPHOINOSITIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-11-04 WO claimed
US-5955453-A Membrane-permeant phosphoinositides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-09-21 US claimed
US-4704396-A 5-HYDROXYTRYPTAMINE; HYPOTENSIVES ELI LILLY AND COMPANY (US) 1987-11-03 US claimed
EP-0228876-A2 Esters of dihydrolysergic acid and related compounds ELI LILLY AND COMPANY (US) 1987-07-15 EP claimed
US-4075340-A ANTIINFLAMMATORY, ANTIARRYTHMIC, ANTICOAGULANTS PARCOR (FR) 1978-02-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230414638-A1 SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF PRKAG2, PRKAB2, PRKAG1 MAPT 2537/4885HTT 3881/4885LMNA 4223/4885
US-11897977-B2 Photolabile barbiturate compounds PPOX, CBR1, CBR3 MAPT 70/4885HTT 2868/4885LMNA 3594/4885
US-20240180932-A1 SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS HSPA9, CS, SQSTM1 MAPT 776/4885HTT 129/4885LMNA 2758/4885
US-20230346942-A1 MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF CRY1, MAPT, PYGL MAPT 2/4885HTT 838/4885LMNA 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.